Thyrocare Q2FY27 Revenue Up 25.1% YoY to ₹270.8 Cr
Thyrocare Technologies Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of ₹270.8 crore, marking a 25.1% year-on-year growth, primarily driven by a 26.7% increase in the Pathology segment. Consolidated EBITDA grew by 24.9% YoY to ₹89.3 crore, and Profit After Tax (PAT) before exceptional items increased by 25.7% YoY to ₹60.2 crore. An exceptional item of ₹45 crore, a non-cash impairment charge related to the proposed sale of the Nuclear Imaging (NHL) business, was recognized. Thyrocare processed 61.6 million tests, a 27.4% YoY increase. The company also launched a Pregnancy Test Kit and is expanding into specialty diagnostics.
Key Highlights
- Consolidated revenue grew 25.1% YoY to ₹270.8 Cr in Q2FY27.
- PAT before exceptional items increased 25.7% YoY to ₹60.2 Cr.
- Processed 61.6 million tests, up 27.4% YoY, reinforcing volume leadership.
- Launched Pregnancy Test Kit and expanding into specialty diagnostics.
- Divestment of Nuclear Imaging business proposed to sharpen focus.
Price Impact
More from THYROCARE